Glenmark seals buyout in South Africa

Glenmark Pharma's South African subsidiary – Bouwer-Bartlett (Pty) Ltd – has acquired seven products and 11 presentations from PD Pharmaceuticals Ltd for an undisclosed amount.

The brands, collectively, are expected to garner sales of $2-3 million in the current financial year. Bouwer-Bartlett, which has obtained global intellectual property rights for the products, will initially market the products within South Africa and gradually sell them in other geographies.

The basket, acquired, comprises anti-diarrhoeal, anti-inflammatory, analgesic, expectorant, anti-protozoal, anti-acid and multi-vitamin products.

Glenn Saldanha, CEO and managing director, Glenmark Pharmaceuticals, said the purchase of the seven PD Pharma products followed Glenmark's acquisition of Bouwer-Bartlett, a sales and marketing company in South Africa in December 2005.